Markets:

News

Articles published by Immunomic Therapeutics, Inc.

Immunomic Therapeutics Announces Presentation on Self-amplifying RNA vaccines using the UNITE® platform for Triple-negative Breast Cancer at SITC 39th Annual Meeting 2024

November 06, 2024

From Immunomic Therapeutics, Inc.

Via Business Wire

Immunomic Therapeutics Reports Positive Results from Its Phase 1 Clinical Trial of ITI-3000 in Patients Diagnosed with Merkel Cell Carcinoma

October 23, 2023

From Immunomic Therapeutics, Inc.

Via Business Wire

Immunomic Therapeutics Doses First Patient in its Phase 1 Clinical Trial of ITI-1001, a pDNA Vaccine for the Treatment of Glioblastoma Multiforme

August 24, 2023

From Immunomic Therapeutics, Inc.

Via Business Wire

Immunomic Therapeutics Announces Presentation on Manufacturing Cell Therapies at Supply Chain and Logistics for Cell Therapy Summit 2023

March 06, 2023

From Immunomic Therapeutics, Inc.

Via Business Wire

Immunomic Therapeutics to Present at Biotech Showcase 2023

January 04, 2023

From Immunomic Therapeutics, Inc.

Via Business Wire

Immunomic Therapeutics Receives FDA Fast Track Designation for ITI-3000, a pDNA Vaccine, in Development for the Treatment of Merkel Cell Carcinoma

November 08, 2022

From Immunomic Therapeutics, Inc.

Via Business Wire

Immunomic Therapeutics Announces Presentation on Nucleic Acid-Based UNITE® Vaccine Platform at Vaccines Summit 2022

October 10, 2022

From Immunomic Therapeutics, Inc.

Via Business Wire

Immunomic Therapeutics Announces the Appointment of Frances Harrison as Senior Vice President, Regulatory Affairs

September 06, 2022

From Immunomic Therapeutics, Inc.

Via Business Wire

Immunomic Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ITI-3000 pDNA Vaccine for the Treatment of Merkel Cell Carcinoma

July 20, 2022

From Immunomic Therapeutics, Inc.

Via Business Wire

Immunomic Therapeutics Appoints Vice President, Cell Therapy

June 07, 2022

From Immunomic Therapeutics, Inc.

Via Business Wire

Immunomic Therapeutics to Participate at World Vaccine Congress Washington 2022

April 14, 2022

From Immunomic Therapeutics, Inc.

Via Business Wire

Immunomic Therapeutics Reports Preclinical Data on Its MCPγV-LT and Her2/Neu DNA Vaccines at the American Association for Cancer Research (AACR) Annual Meeting 2022

April 08, 2022

From Immunomic Therapeutics, Inc.

Via Business Wire

Immunomic Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022

March 31, 2022

From Immunomic Therapeutics, Inc.

Via Business Wire

Immunomic Therapeutics to present at the BIO CEO & Investor Conference 2022

February 11, 2022

From Immunomic Therapeutics, Inc.

Via Business Wire

Immunomic Therapeutics Announces Clinical Trial of ITI-3000 for the Treatment of Merkel Cell Carcinoma

February 07, 2022

From Immunomic Therapeutics, Inc.

Via Business Wire

Immunomic Therapeutics’ CBO to present at the 14th Annual Biotech Showcase Event

January 06, 2022

From Immunomic Therapeutics, Inc.

Via Business Wire

Immunomic Therapeutics Announces Open Enrollment for RENEW Clinical Study of CMV RNA-Pulsed Dendritic Cell Vaccine for the Treatment of Newly-Diagnosed Glioblastoma Patients

November 30, 2021

From Immunomic Therapeutics, Inc.

Via Business Wire

Immunomic Therapeutics Announces Collaboration With iOncologi

November 23, 2021

From Immunomic Therapeutics, Inc.

Via Business Wire

Immunomic Therapeutics Presents Clinical Data From ATTAC Studies in GBM at the 2021 Society for Neurology (SNO) Annual Meeting

November 18, 2021

From Immunomic Therapeutics, Inc.

Via Business Wire

Immunomic Therapeutics Expands Board of Directors with Appointments of Two New Members

July 27, 2021

From Immunomic Therapeutics, Inc.

Via Business Wire

Immunomic’s Academic Collaborator Dr. John Sampson Recognized as “World Expert” in Glioblastoma as Part of Glioblastoma Awareness Day

July 21, 2021

From Immunomic Therapeutics, Inc.

Via Business Wire

Immunomic Therapeutics Strengthens Leadership Team with Appointment of Robert Newman as Chief Business Officer

July 19, 2021

From Immunomic Therapeutics, Inc.

Via Business Wire

Immunomic Therapeutics to Participate at World Vaccine Congress Washington 2021

April 27, 2021

From Immunomic Therapeutics, Inc.

Via Business Wire

Immunomic Therapeutics Announces License Agreement With Lineage Cell Therapeutics for Cancer Immunotherapy

April 20, 2021

From Immunomic Therapeutics, Inc.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.